Skip to main content
SpringerLink
Log in

Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The relationship between drugs and pre-existing liver disease is complex, particularly when increased liver tests (LTs) or new symptoms emerge in patients with pre-existing liver disease during drug therapy. This requires two strategies to assess whether these changes are due to drug-induced liver injury (DILI) as a new event or due to flares of the underlying liver disease. Lacking a valid diagnostic biomarker, DILI is a diagnosis of exclusion and requires causality assessment by RUCAM, the Roussel Uclaf Causality Assessment Method, to establish an individual causality grading of the suspected drug(s). Flares of pre-existing liver disease can reliably be assessed in some hepatotropic virus infections by polymerase chain reaction (PCR) and antibody titers at the beginning and in the clinical course to ascertain flares during the natural course of the disease. Unfortunately, flares cannot be verified in many other liver diseases such as alcoholic liver disease, since specific tests are unavailable. However, such a diagnostic approach using RUCAM applied to suspected DILI cases includes clinical and biological markers of pre-existing liver diseases and would determine whether drugs or underlying liver diseases caused the LT abnormalities or the new symptoms. More importantly, a clear diagnosis is essential to ensure effective disease management by drug cessation or specific treatment of the flare up due to the underlying disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999.

    Google Scholar 

  2. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–30.

    Article  CAS  PubMed  Google Scholar 

  3. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, Gonzalez-Grande R, Pizarro A, Durán JA, Jiménez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmerón J, Martin-Vivaldi R, Spanish Group for the Study of Drug-induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–21.

    Article  PubMed  Google Scholar 

  4. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H, Gu J, Serrano J. Features and outcomes of 889 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology. 2015;148:1340–52. doi:10.1053/j.gastro.2015.03.006.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Teschke R, Andrade R. Editorial. Drug-induced liver injury: expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment. Gastroenterology. 2015;148:1271–3. doi:10.1053/j.gastro.2015.04.027.

    Article  PubMed  Google Scholar 

  6. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109:950–66.

    Article  PubMed  Google Scholar 

  7. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(1). doi:10.3390/ijms17010014. Special issue: Drug, herb, and dietary supplement hepatotoxicity. Available at: http://www.mdpi.com/1422-0067/17/1/14.

  8. Björnsson ES. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci. 2016;17:224. doi:10.3390/ijms17020224.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Andrade RJ. Clinical features, case characterization, and risk factors in drug induced liver injury. Int J Mol Sci. 2016 (in press).

  10. Watkins PB, Merz M, Avigan MI, Kaplowitz N, Regev A, Senior JR. The clinical liver safety assessment best practices workshop: rationale, goals, accompliments and the future. Drug Saf. 2014;37(Suppl 1):S1–7.

    Article  PubMed  Google Scholar 

  11. Senior JR. Evolution of the food and drug administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf. 2014;37(Suppl 1):S9–17.

    Article  PubMed  Google Scholar 

  12. Avigan MI, Bjornsson ES, Pasanen M, Cooper C, Andrade RJ, Watkins PB, Lewis JH, Merz M. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials. Drug Saf. 2014;37(Suppl 1):S19–31.

    Article  PubMed  Google Scholar 

  13. Merz M, Lee KR, Kullak-Ublick GA, Brueckner A, Watkins PB. Methodology to assess clinical liver safety data. Drug Saf. 2014;37(Suppl 1):S33–45.

    Article  PubMed  Google Scholar 

  14. Regev A, Seeff LB, Merz M, Ormarsdottir S, Aithal GP, Gallivan J, Watkins PB. Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf. 2014;37(Suppl 1):S47–56.

    Article  PubMed  Google Scholar 

  15. Kullak-Ublick GA, Merz M, Griffel L, Kaplowitz N, Watkins PB. Liver safety assessment in special populations (hepatitis B, C, and oncology trials). Drug Saf. 2014;37(Suppl 1):S57–62.

    Article  PubMed  Google Scholar 

  16. Fontana RJ. Acute liver failure including acetaminophen overdose. Med Clin North Am. 2008;92:761–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451–5.

    Article  PubMed  Google Scholar 

  18. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Sem Liver Dis. 2009;29:337–47.

    Article  CAS  Google Scholar 

  19. Younossi ZM, Stepanova M, Affendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–30.

    Article  PubMed  Google Scholar 

  20. Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, Volk ML. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol. 2015;49:690–6.

    Article  PubMed  Google Scholar 

  21. Franz CC, Egger S, Born C, Rätz Bravo AE, Krähenbühl S. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2012;68:179–88.

    Article  CAS  PubMed  Google Scholar 

  22. Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, Sanchez de la Cuesta F, Spanish Group of Therapeutic Management in Liver Diseases. Drug use for non-hepatic associated conditions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2003;59:71–6.

    PubMed  Google Scholar 

  23. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE. Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871–6.

    Article  CAS  PubMed  Google Scholar 

  24. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WY, Wong PC, Tam CM, Leung CC, Lai CL. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology. 2000;31:201–6.

    Article  CAS  PubMed  Google Scholar 

  25. McGlynn KA, Lustbader ED, Sharrar RG, Murphy EC, London WT. Isoniazid prophylaxis in hepatitis B carriers. Am Rev Respir Dis. 1986;134:666–8.

    CAS  PubMed  Google Scholar 

  26. Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol. 2002;97:1198–203.

    Article  PubMed  Google Scholar 

  27. Wu JC, Lee SD, Yeh PF, Chan CY, Wang YJ, Huang YS, Tsai YT, Lee PY, Ting LP, Lo KJ. Isoniazid–rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology. 1990;98:502–4.

    CAS  PubMed  Google Scholar 

  28. Amarapurkar DN, Prabhudesai PP, Kalro RH, Desai HG. Antituberculosis drug-induced hepatitis and HBsAg carriers. Tuberc Lung Dis. 1993;74:215–6.

    Article  CAS  Google Scholar 

  29. Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CL, Lin TP, Lee SD. A prospective clinical study of isoniazid–rifampicin–pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol. 1997;12:87–91.

    Article  CAS  PubMed  Google Scholar 

  30. Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clin Infect Dis. 2004;38(Suppl 2):S104–8.

    Article  CAS  PubMed  Google Scholar 

  31. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1278–92.

    Article  Google Scholar 

  32. Russo MW, Watkins PB. Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology. 2004;126:1477–80.

    Article  PubMed  Google Scholar 

  33. Chalasani N, Teal E, Hall SD. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastoenterol. 2005;100:1317–21.

    Article  CAS  Google Scholar 

  34. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci. 2005;329:62–5.

    Article  PubMed  Google Scholar 

  35. Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, Kwon OJ. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest. 2005;127:1304–11.

    CAS  PubMed  Google Scholar 

  36. Kramer JR, Giordano TP, Souchek J, El-Serag HB. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol. 2005;42:309–14.

    Article  PubMed  Google Scholar 

  37. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroent Hepatol. 2006;4:902–7.

    Article  CAS  Google Scholar 

  38. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR, on behalf of the ATS Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculous therapy. Am J Crit Car Med. 2006;174:935–52.

    Article  CAS  Google Scholar 

  39. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806–15.

    Article  CAS  PubMed  Google Scholar 

  40. Hyashi PH. Drug-Induced Liver Injury Network: causality assessment, criteria, and experience in the United States. Int J Mol Sci. 2016;17(2):201. doi:10.3390/ijms17020201.

    Article  Google Scholar 

  41. Teschke R, Frenzel C, Wolff A, Eickhoff A, Schulze J. Drug induced liver injury: accuracy of diagnosis in published reports. Ann Hepatol. 2014;13:248–55.

    PubMed  Google Scholar 

  42. Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis. 2014;34:123–33. doi:10.1055/s-0034-137595454. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24879978.

  43. Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics. 2009;10:1467–87. doi:10.2217/pgs.09.111.

    Article  CAS  PubMed  Google Scholar 

  44. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58:388–96.

    Article  CAS  PubMed  Google Scholar 

  45. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47:2003–9.

    Article  CAS  PubMed  Google Scholar 

  46. Agarwal VK, McHutchison JG, Hoofnagle JH, Drug-Induced Liver Injury Network (DILIN). Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8:463–670.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut. 1999;44:731–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reactions reported in one English health region. Br Med J. 1999;319:1541.

    Article  CAS  Google Scholar 

  49. Dalton HR, Fellows HJ, Stableforth W, Joseph M, Thurairajah PH, Warshow U, Hazeldine S, Remnarace R, Ijaz S, Hussaini SH, Bendall RP. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther. 2007;26:1429–35.

    Article  CAS  PubMed  Google Scholar 

  50. Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, Engle RE, Nguyen H, Emerson SU, Purcell RH, Tillmann HL, Gu J, Serrano J, Hoofnagle JH, for the Drug-Induced Liver Injury Network (DILIN). Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665–72.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Hoofnagle JH, Nelson KE, Purcell RH. Review article: hepatitis E. N Engl J Med. 2012;367:1237–44.

    Article  CAS  PubMed  Google Scholar 

  52. Au JS, Navarro VJ, Rossi S. Review article: drug induced liver injury—its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther. 2011;34:11–20.

    Article  CAS  PubMed  Google Scholar 

  53. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331–6.

    Article  PubMed  Google Scholar 

  54. Teschke R, Schulze J, Eickhoff A, Wolff A, Frenzel C. Review article: mysterious Hawaii liver disease case—naproxen overdose as cause rather than OxyELITE Pro? J Liver Clin Res. 2015;2. Available at: http://www.jscimedcentral.com/Liver/liver-2-1013.pdf.

  55. Teschke R, Schwarzenboeck A, Frenzel C, Schulze J, Eickhoff A, Wolff A. The mystery of the Hawaii liver disease cluster in summer 2013: a pragmatic and clinical approach to solve the problem. Ann Hepatol. 2016;15:91–118.

    Article  PubMed  Google Scholar 

  56. Chen EY, Baum K, Collins W, Löve A, Merz M, Olafsson S, Björnsson ES, Lee WM. Hepatitis E masquerading as drug–induced liver injury. Hepatology. 2012;56:2420–3.

    Article  PubMed  Google Scholar 

  57. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiodt FV, Ostapowicz G, Shakil AO, Lee WM, Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicentre, prospective study. Hepatology. 2005;42:1364–72.

    Article  CAS  PubMed  Google Scholar 

  58. Teschke R, Stutz G, Strohmeyer G. Increased paracetamol-induced hepatotoxicity after chronic alcohol consumption. Biochem Biophys Res Commun. 1979;91:368–74.

    Article  CAS  PubMed  Google Scholar 

  59. Stine JG, Chalasani N. Chronic liver injury induced by drugs: a systematic review. Liver Int. 2015;35:2343–53.

    Article  CAS  PubMed  Google Scholar 

  60. Goldberg DS, Forde KA, Carbonari DM, Lewis JD, Leidl KB, Reddy KR, Haynes K, Roy J, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA, Lo Re V 3rd. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated healthcare system. Gastroenterology. 2015;148:1353–61.

    Article  PubMed  PubMed Central  Google Scholar 

  61. FDA Guidance for Industry. Clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling. 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM337169.pdf. Accessed 15 Feb 2016.

  62. FDA Guidance for Industry. Drug-induced liver injury: premarketing clinical evaluation. 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf. Accessed 15 Feb 2016.

  63. Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a US multicenter, prospective study. Hepatology. 2010;52:2065–76.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM. AASLD guidelines of chronic hepatitis B. Hepatology. 2016;63:261–83.

    Article  PubMed  Google Scholar 

  65. EASL. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.

    Article  Google Scholar 

  66. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41:690–5.

    Article  CAS  PubMed  Google Scholar 

  67. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56:374–80.

    Article  PubMed  Google Scholar 

  68. Myers RP, Shaheen AAM, Li B, Dean S, Quan H. Impact of liver disease, alcohol abuse, and unintentional ingestions on the outcomes of acetaminophen overdose. Clin Gastroenterol Hepatol. 2008;6:918–25.

    Article  PubMed  Google Scholar 

  69. Hayashi PH, Fontana RJ, Chalasani NP, Stolz AA, Talwalkar JA, Navarro VJ, Lee WM, Davern TJ, Kleiner DE, Gu J, Hoofnagle JH, US Drug-Induced Liver Injury Network Investigators. Under-reporting of poor adherence to monitoring guidelines for severe cases of Isoniazid hepatotoxicity. Clin Gastroenterol Hepatol. 2015;13:1676–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Teschke R, Frenzel C, Glass X, Schulze J, Eickhoff A. Greater celandine hepatotoxicity: a clinical review. Ann Hepatol. 2012;11:838–48.

    PubMed  Google Scholar 

  71. Dyson JK, Hutchinson J, Harrison L, Rotimi O, Tiniakos D, Foster GR, Aldersley MA, McPherson S. Liver toxicity associated with sofobuvir, an NS5A inhibitor and ribavirin use. J Hepatol. 2016;64:234–8.

    Article  CAS  PubMed  Google Scholar 

  72. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010;51:615–20.

    Article  CAS  PubMed  Google Scholar 

  73. Yu K, Geng X, Chen M, Zhang J, Wang B, Ilic K, Tong W. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos. 2014;42:744–50.

    Article  PubMed  Google Scholar 

  74. Chen M, Suzuki A, Boriak J, Andrade RJ, Lucena MI. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015;63:503–14.

    Article  CAS  PubMed  Google Scholar 

  75. Schlatterer-Häner C. Dose adaptation of drugs in patients with liver disease. Thesis University Basel, 2009. Available at: http://edoc.unibas.ch/926/1/Dose_Adaptation_of_Drugs_in_Patients_with_Liver_Disease.pdf. Last accessed 15 Feb 2016.

  76. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147–61.

    Article  CAS  PubMed  Google Scholar 

  77. Delcò F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S. Drug adjustment in patients with liver disease. Drug Saf. 2005;28:529–45.

    Article  PubMed  Google Scholar 

  78. Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Saf. 1997;17:47–73.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Internal Medicine II, Klinikum Hanau, Leimenstrasse 20, 63450, Hanau, Germany

    Rolf Teschke

  2. Academic Teaching Hospital of the Medical Faculty, Goethe University Frankfurt/Main, Frankfurt/Main, Germany

    Rolf Teschke

  3. Pharmacovigilance Consultancy, Paris, France

    Gaby Danan

Authors
  1. Rolf Teschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gaby Danan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rolf Teschke.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this review article.

Conflict of interest

Rolf Teschke and Gaby Danan have no conflicts of interest that are directly relevant to the content of this review article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Teschke, R., Danan, G. Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease. Drug Saf 39, 729–744 (2016). https://doi.org/10.1007/s40264-016-0423-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-016-0423-z

Keywords

Search

Navigation